Myeloid-derived suppressor cells (MDSCs) 1 are critical mediators of tumor-induced immune dysfunction and cancer progression. 2 MDSCs represent a heterogeneous population of immature myeloid cells (iMC) involving precursors of macrophages, granulocytes, and dendritic cells (DC) capable of immunosuppression, 1, 3 and using diverse suppressive factors, including indoleamine 2,3-dioxigenase (IDO1), IL-10, arginase 1 (ARG1), inducible nitric oxide synthase (iNOS, NOS2), nitric oxide (NO), and reactive oxygen species (ROS), to suppress immune responses at the tumor sites. 1 In analogy to the heterogeneous mechanism of MDSC function, the induction of MDSC can be triggered by multiple factors with nominally-opposing functions, including interleukin-1β (IL-1β), IL-6, IL-10, TLR-ligands, macrophage colony stimulating factor (M-CSF) and vascular endothelial growth factor (VEGF), or prostaglandin E 2 (PGE 2 ). 1 PGE 2 , a ubiquitous cancer-associated inflammatory mediator produced by cancer cells, stroma, and infiltrating myeloid cells (reviewed in ref. 4) , was previously shown to prevent the development of functional DCs in the human system, 5 and to promote MDSC accumulation in cancer-bearing mice. 6 Our two recent reports 7, 8 demonstrate that PGE 2 is both required and sufficient to redirect the differentiation of human dendritic cells into monocytic MDSCs (see Figure 1) . It also mediates the induction of MDSC-associated suppressive factors by additional MDSC-inducing stimuli, in a mechanism involving the establishment of a positive feedback loop between PGE 2 and cyclooxygenase (COX)-2 7 , the key regulator of PGE 2 production. 4 We observed 7 that the frequencies of MDSCs in peritoneal ascites from ovarian cancer patients strongly correlate with local expression of COX2 and production of PGE 2 . The ability of cancer microenvironment to induce MDSCs phenotype and functions in differentiating myeloid precursors (monocytes) ex vivo is abolished by inhibitors of cyclooxygenases (such as indomethacin) or selective inhibitors of COX2. Moreover, the presence of synthetic PGE 2 from the therapeutic standpoint, the positive feedback between active COX2 and autocrine production of endogenous PGE 2 proved to be essential for the MDSC stability. Even short-term (overnight) treatment of the fully-developed MDSCs isolated from cancer patients using COX2 inhibitors or EP2 and EP4 antagonists abrogated endogenous production of PGE 2 , suppressed the expression of IL-10, IDO1, NOS2 and endogenous COX2, and reversed the CTL-suppressive functions of cancer-isolated MDSCs. Cancer-associated MDSCs uniformly expressed high levels of CXCR4, 8 known to be present on blood MDSCs in cancerbearing individuals, 9 and showed strong migratory responsiveness to CXCL12. 8 While cancer environment induced high levels of CXCR4 on differentiating MDSCs, the CXCR4 expression and responsiveness of the ascites-isolated MDSCs to CXCL12 (recombinant or present in cancer ascites) were blocked by their pre-treatment with COX2 inhibitors.
Apart from driving the development of CXCR4 + MDSCs and promoting their stability, PGE 2 proved to be the key factor promoting the production of CXCL12/ SDF-1 (CXCR4 ligand) in cancer microenvironment. The concentrations of CXCL12 in cancer ascites samples were strongly correlated with the local production of PGE 2 , while the ability of the ascites cells to produce CXCL12 and attract CXCR4 + MDSCs was blocked by COX2 inhibition. 8 The dependence of human cancerassociated MDSCs on undisturbed COX2 activity helps to circumvent the obstacles to effective targeting the MDSC-associated immuno-suppression imposed by their multi-factorial origin and multiple mechanisms of suppressive function, 1 helping to design effective immune therapies of advanced ovarian cancer and potentially other malignancies. Our current data also facilitates the generation of large numbers of MDSCs for the immunotherapy of autoimmune, and inflammatory diseases, or transplant rejection. The current data and the previously-documented role of PGE 2 in the induction, recruitment and functions of Tregs, and its inhibitory impact on the development, attraction, and functions of type-1 immune cells (CTLs, Th1 and NK cells; reviewed in ref. 4) , suggest that PGE 2 -targeting is an important element of effective cancer immunotherapies. and/or cancer-produced PGE 2 or PGE 2 inducers drive the early induction of COX2 in local myeloid cells (monocytes, macrophages, immature DCs), promoting their production of suppressive factors (IDO1, IL-10, ARG1, NOS2 and PGE 2 itself), and acquisition of suppressive functions. The EP2-and EP4-dependent signals are also critical in the induction and persistence of functional CXCR4 on monocytic cells and for the production of CXCL12/SDF-1 in cancer environment. These processes are further amplified by the de novo-produced endogenous PGE 2 , now produced at high levels by MDSCs themselves, thereby creating a positive feedback loop, leading to accumulation of MDSCs in cancer environment. In addition to inducing other suppressive factors, PGE 2 also directly suppresses CTL development and functions, acting via EP2 and EP4 receptors. The key role of the EP2-and EP4-mediated COX2-PGE 2 feedback to control multiple aspects of MDSC function provides for convenient targets to control MDSC-associated immune dysfunction in cancer immunotherapy.
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